The 7th National Hellenic oncology Congress ΕΟΠΕ just began , all of us and our special distinguished guest expert and amazing person Charu Aggarwal, MD, MPH, FASCO are looking forward to welcome all of you!! #some #lcsm
Marita Lykka MD ESMO - Eur. Oncology IASLC ASCO OncoAlert

Thrilled to be invited to speak at the 7th Hellenic Conference of Oncology ESMO - Eur. Oncology. Looking forward to a great meeting with Giannis Mountzios, Marita Lykka MD and many more.
Hellenic Oncological Society of Diaspora-HeL.O.DI #LiquidBx International Society of Liquid Biopsy

I truly can’t wait for you to join us at #ASCO24 . It promises to be a vibrant platform to share groundbreaking research, foster collaboration, and advance our mission to conquer cancer. See you in Chicago!

Great to see lung cancer research highly represented at the ASCO plenary session. This has been a long time coming!
#LCSM Winship Cancer Institute of Emory University.

Ooh, love the title “Are we on BEAT” discussed by Melina Marmarelis ! This will be a great session #ASCO24

And the time is now for #ASCO24 ! Abstract titles out now! ⏰
meetings.asco.org/meetings/2024-…

Looking forward to an exciting meeting ! Hem-Onc Fellows Network LungCancerRx 🫁💊 OncoAlert OncoDaily Vivek Subbiah, MD Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Charu Aggarwal, MD, MPH, FASCO Eric K. Singhi, MD

#Alectinib now FDA Oncology approved based off #ALINA trial.

Alectinib vs Chemo post resection in NSCLC, Stg Ib-IIIA:

- Alectinib for 2 yrs
- Improved DFS in all subgroups: HR0.24
- Improved CNS DFS HR: 0.22
- New Soc

Ben Solomon #lcsm #onctwitter #medtwitter

Join our dream team 💭
Stephen V Liu, MD Charu Aggarwal, MD, MPH, FASCO Christine Lovly, MD, PhD So Yeon Kim Zosia Piotrowska I.DagogoJackMD Christine Bestvina
Ticiana Batista (Leal) Benjamin Levy Adam J. Schoenfeld Angel Qin

👉 Register now: ms.spr.ly/6010csMNM
#PLCClive24

#ELCC24 Great discussion of #ADC toxicity from Dr. Jarushka Naidoo, noting that each component of the antibody drug conjugate (target, Ab, linker, payload) will impact toxicity. Good awareness of ILD, which is dose dependent, but many other unique toxicities to watch. IASLC ESMO - Eur. Oncology

#ELCC24 Dr. Maria Gemelli presents the I-STOP study: retrospective analysis of pts with NSCLC who completed 2y of PD(L)1 monotherapy. 73% continued beyond 2y but similar PFS/OS. No pts d/c due to irAE after 2y. Echoes work from Dr. Charu Aggarwal, MD, MPH, FASCO Lova Sun. IASLC ESMO - Eur. Oncology

Honored to be nominated for Healio 2024 Woman Disruptor of the Year, amongst women I admire and have inspired me to break ceilings.
Tatiana Prowell, MD Reshma Jagsi Aparna Raj Parikh Sophia George, PhD #ElizabethNichols Hematology & Oncology Women Physicians Group—HOWPG #WomeninOncology #WomenInOncology

ESMO - Eur. Oncology Trinity College Dublin St James's Hospital Trinity St James's Cancer Institute IASLC Lung Cancer Europe .Jordi Remon provided a comprehensive overview of liquid biopsy covering genomic profiling beyond baseline, impact on treatment strategies and minimal residual disease (3/6)

#ELCC24 #LCSM #ESMOAmbassadors ESMO - Eur. Oncology

Really enjoyed taking part in a very busy #ELCC24 . Don't forget to check out the ESMO Daily Reporter (dailyreporter.esmo.org) & the virtual congress platform for anything that you may have missed (esmo.org/meeting-calend…).

Looking forward to #ELCC25 !

#LCSM #ESMOAmbassadors

We all concur, Charu Aggarwal, MD, MPH, FASCO ! Jill Feldman -- hearty congratulations from all your friends at ICAN, the Biomarker Collaborative, the Exon 20 Group, and the MET Crusaders!❤️💚💜💙

Charu Aggarwal, MD, MPH, FASCO ASCO Awww, thank you so much Charu! My advocacy has involved in large part because researchers & physicians like you have welcomed us into discussions, listened to our input & treated us as genuine partners. The unwavering support & collaboration have fueled my passion for advocacy❤️

I cannot think of anyone else more deserving of this ASCO Patient Advocate Award. Jill Feldman - it is an honor to know you, to learn from you and thank you for everything you have done and continue to do for patients with Lung Cancer. Bravo!! You are an inspiration!!

Agreed, Charu Aggarwal, MD, MPH, FASCO. However, until the role of ctDNA in the early-stage setting becomes more firmly defined and widely available, it is immediately imperative to ensure that we maximize our ability to perform upfront appropriate #NGS and #IHC testing during initial biopsy

Terrific discussion by Jonathan Spicer MD PhD ESMO - Eur. Oncology #ELCC24 summarizing perioperative chemo-IO in #NSCLC , few hours before a terrific paper in JAMA Oncology ! Neoadjuvant chemo-immunotherapy is superior to neoadjuvant chemotherapy across surgical, pathological and efficacy outcomes for

#ELCC24 Noemi Reguart performs a deep dive analysis on a hard topic and an unmet medical need: New molecular targets for squamous NSCLC:

⚡️Actionable RTK alterations
⚡️Early-phase FGFR inhibitors
⚡️2nd gen PRMT5 inhibitors
⚡️BET/NSD3 inh
⚡️PD1/VEGF Bites
⚡️Biomarkers lacking!